$SEEL
Seelos Therapeutics Inc Stock $seel

$seel Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000101749117000125 Filed on November 02, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$0.00	$0.00	$4.317M
YoY Change		-100.0%	239.12%
Cost Of Revenue			$111.0K
YoY Change			-21.83%
Gross Profit			$826.0K
YoY Change			-26.97%
Gross Profit Margin			19.13%
Selling, General & Admin	$2.410M	$1.760M	$1.550M
YoY Change	26.84%	13.55%	-35.68%
% of Gross Profit			187.65%
Research & Development	$240.0K	$1.960M	$170.0K
YoY Change	-60.66%	1052.94%	-96.31%
% of Gross Profit			20.58%
Depreciation & Amortization	$20.00K	$20.00K	$70.00K
YoY Change	-118.18%	-71.43%	0.0%
% of Gross Profit			8.47%
Operating Expenses	$2.650M	$3.716M	$1.720M
YoY Change	5.58%	116.05%	-75.51%
Operating Profit		-$3.716M	-$1.720M
YoY Change		116.05%	-70.81%
Interest Expense	-$50.00K	$3.000K	-$234.0K
YoY Change	-102.27%	-101.28%	-12.36%
% of Operating Profit
Other Income/Expense, Net	$100.0K	-$293.0K	$124.0K
YoY Change		-336.29%	-85.55%
Pretax Income	-$2.600M	-$4.010M	-$1.600M
YoY Change	712.5%	150.63%	-68.19%
Income Tax			$1.000K
% Of Pretax Income
Net Earnings	-$2.450M	-$3.832M	-$1.291M
YoY Change	716.67%	196.82%	-74.35%
Net Earnings / Revenue			-29.91%
Basic Earnings Per Share
Diluted Earnings Per Share	-$4.804M	-$8.705M	-$5.864M
COMMON SHARES
Basic Shares Outstanding	15.22M shares	12.78M shares	66.35M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.330M	$8.460M	$5.610M
YoY Change	202.87%	50.8%	-3.44%
Cash & Equivalents	$6.331M	$8.463M	$5.614M
Short-Term Investments
Other Short-Term Assets	$260.0K	$230.0K	$420.0K
YoY Change	-83.23%	-45.24%	-74.39%
Inventory			$800.0K
Prepaid Expenses
Receivables			$398.0K
Other Receivables			$0.00
Total Short-Term Assets	$6.592M	$8.688M	$7.236M
YoY Change	81.4%	20.07%	-11.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$79.00K	$100.0K	$1.091M
YoY Change	-51.83%	-90.83%	-15.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$35.00K	$35.00K	$83.00K
YoY Change	-41.67%	-57.83%	-41.13%
Total Long-Term Assets	$114.0K	$135.0K	$1.174M
YoY Change	-89.31%	-88.5%	-18.19%
TOTAL ASSETS
Total Short-Term Assets	$6.592M	$8.688M	$7.236M
Total Long-Term Assets	$114.0K	$135.0K	$1.174M
Total Assets	$6.706M	$8.823M	$8.410M
YoY Change	42.68%	4.91%	-12.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$60.00K	$260.0K	$1.430M
YoY Change	-92.11%	-81.82%	240.48%
Accrued Expenses	$650.0K	$783.0K	$3.144M
YoY Change	-51.24%	-75.1%	9.59%
Deferred Revenue	$12.00K
YoY Change
Short-Term Debt	$0.00	$0.00	$7.370M
YoY Change	-100.0%	-100.0%	175.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.583M	$1.814M	$12.61M
YoY Change	-85.98%	-85.61%	83.89%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$58.00K	$54.00K	$80.00K
YoY Change	-23.68%	-32.5%	-57.89%
Total Long-Term Liabilities	$58.00K	$54.00K	$80.00K
YoY Change	-23.68%	-32.5%	-57.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.583M	$1.814M	$12.61M
Total Long-Term Liabilities	$58.00K	$54.00K	$80.00K
Total Liabilities	$2.335M	$2.504M	$15.95M
YoY Change	-80.89%	-84.3%	-8.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$316.0M	-$313.5M	-$316.0M
YoY Change	-0.1%	-0.78%	3.09%
Common Stock	$320.4M	$319.9M	$308.5M
YoY Change	3.75%	3.69%	3.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.371M	$6.319M	-$7.537M
YoY Change
Total Liabilities & Shareholders Equity	$6.706M	$8.823M	$8.410M
YoY Change	42.68%	4.91%	-12.4%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$2.450M	-$3.832M	-$1.291M
YoY Change	716.67%	196.82%	-74.35%
Depreciation, Depletion And Amortization	$20.00K	$20.00K	$70.00K
YoY Change	-118.18%	-71.43%	0.0%
Cash From Operating Activities	-$2.480M	-$3.020M	-$860.0K
YoY Change	-8.49%	251.16%	-86.95%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$210.0K	$250.0K	$0.00
YoY Change			-100.0%
Cash From Investing Activities	$210.0K	$250.0K	$0.00
YoY Change	2000.0%		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	130.0K	3.420M	3.750M
YoY Change	-115.66%	-8.8%	-24.85%
NET CHANGE
Cash From Operating Activities	-2.480M	-3.020M	-860.0K
Cash From Investing Activities	210.0K	250.0K	0.000
Cash From Financing Activities	130.0K	3.420M	3.750M
Net Change In Cash	-2.140M	650.0K	2.890M
YoY Change	-39.38%	-77.51%	-278.4%
FREE CASH FLOW
Cash From Operating Activities	-$2.480M	-$3.020M	-$860.0K
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$2.480M	-$3.020M	-$860.0K
YoY Change	-8.49%	251.16%	-86.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	apri	Aggregate Liability Limitation Indemnification Claims AggregateLiabilityLimitationIndemnificationClaims	2000000	USD
	apri	Disposal Group Including Discontinued Operation Payments Recognized For Transition Services DisposalGroupIncludingDiscontinuedOperationPaymentsRecognizedForTransitionServices	500000	USD
	apri	Disposal Group Including Discontinued Operation Payments Recognized For Transition Services DisposalGroupIncludingDiscontinuedOperationPaymentsRecognizedForTransitionServices	500000	USD
CY2017Q1	apri	Disposal Group Including Discontinued Operations Disposal During Period Carrying Value Of Assets DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodCarryingValueOfAssets	1578000	USD
CY2017Q1	apri	Disposal Group Including Discontinued Operations Disposal During Period Liabilities Transferred DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodLiabilitiesTransferred	1186000	USD
	apri	Disposal Group Including Discontinued Operations Disposal During Period Liabilities Transferred After Closing Date DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodLiabilitiesTransferredAfterClosingDate	1100000	USD
CY2017Q3	apri	Entity Public Float Primary Public Offerings Of Securities Threshold EntityPublicFloatPrimaryPublicOfferingsOfSecuritiesThreshold	75000000	USD
CY2017Q1	apri	Expected Payments For Transition Services Number Of Quarterly Payments ExpectedPaymentsForTransitionServicesNumberOfQuarterlyPayments	2	payment
CY2017Q1	apri	Expected Payments Received For Delivery Of Product Related Inventory ExpectedPaymentsReceivedForDeliveryOfProductRelatedInventory	700000	USD
CY2017Q1	apri	Expected Payments Received For Transition Services ExpectedPaymentsReceivedForTransitionServices	500000	USD
	apri	Gain Losseson Extinguishmentof Debt Non Cash Operating GainLossesonExtinguishmentofDebtNonCashOperating	0	USD
	apri	Gain Losseson Extinguishmentof Debt Non Cash Operating GainLossesonExtinguishmentofDebtNonCashOperating	-422000	USD
	apri	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	9367000	USD
	apri	Noncash Financing Activities Reclassification Of Warrants To Equity NoncashFinancingActivitiesReclassificationOfWarrantsToEquity	0	USD
	apri	Noncash Financing Activities Reclassification Of Warrants To Equity NoncashFinancingActivitiesReclassificationOfWarrantsToEquity	798000	USD
CY2016Q1	apri	Proceeds From Issuance Of Sale Of Equity Net Of Transaction Costs ProceedsFromIssuanceOfSaleOfEquityNetOfTransactionCosts	9600000	USD
CY2017Q2	apri	Proceeds From Sale Of Product Related Inventory ProceedsFromSaleOfProductRelatedInventory	709000	USD
CY2017Q2	apri	Proceeds From Sale Of Product Related Inventory ProceedsFromSaleOfProductRelatedInventory	700000	USD
CY2017Q3	apri	Public Float Primary Public Offerings Of Securities Percent Of Public Float Eligible To Be Raised If Under Threshold PublicFloatPrimaryPublicOfferingsOfSecuritiesPercentOfPublicFloatEligibleToBeRaisedIfUnderThreshold	0.3333
CY2017Q1	apri	Purchase Agreement Maximum Potential Proceeds From Divestiture PurchaseAgreementMaximumPotentialProceedsFromDivestiture	12700000	USD
CY2016Q4	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	142000	USD
CY2017Q3	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	64000	USD
	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.1133
CY2017Q3	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	7270070	shares
CY2017Q3	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	3.85
	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	1.60
CY2016Q4	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	15.19
CY2017Q3	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.85
	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice	52.50
CY2017Q3	apri	Shelf Registration Statement Available Amount ShelfRegistrationStatementAvailableAmount	100000000	USD
CY2014Q3	apri	Shelf Registration Statement Available Amount ShelfRegistrationStatementAvailableAmount	100000000	USD
	apri	Warrant Liability Reclassified To Stockholders Equity WarrantLiabilityReclassifiedToStockholdersEquity	798000	USD
CY2017Q3	apri	Working Capital WorkingCapital	6900000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001017491
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15215517	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	APRICUS BIOSCIENCES, INC.
	dei	Trading Symbol TradingSymbol	APRI
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	686000	USD
CY2017Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	262000	USD
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	282000	USD
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	56000	USD
CY2016Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	614000	USD
CY2017Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	668000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1236000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	783000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	783000	USD
CY2017Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	601000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	308784000	USD
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	319845000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	903000	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	103000	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	287000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	333000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1427000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	332000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	903000	USD
CY2016Q4	us-gaap	Assets Assets	4700000	USD
CY2017Q3	us-gaap	Assets Assets	8823000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	3634000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	8688000	USD
CY2016Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	1370000	USD
CY2017Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	9000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3887000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5614000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2087000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8463000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1727000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6376000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	12000000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	818000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	80000	USD
CY2017Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	7270070	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7733205	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15029052	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7733205	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15029052	shares
CY2016Q1	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	10000000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	15000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	259000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	131000	USD
	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	280000	USD
	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	0	USD
CY2016Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	134000	USD
CY2017Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	0	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	217000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	98000	USD
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	846000	USD
CY2017Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	636000	USD
CY2017Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	600000	USD
	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	12317000	USD
CY2016Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	0.05
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	0.03
CY2017Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	0.01
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	1.11
CY2016Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	842000	USD
CY2017Q3	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	0	USD
CY2017Q3	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	12709000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.17
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.26
CY2016Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-626000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5063000	USD
CY2017Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	296000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	588000	USD
CY2016Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-422000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1550000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5878000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1756000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4799000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1596000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-7344000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-4009000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-9150000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.24
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.20
CY2017Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.30
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.85
CY2016Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	305000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	210000	USD
CY2017Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	177000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	11917000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	105000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-425000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1103000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-583000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-318000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	54000	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-135000	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-18000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-25000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	15000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-22000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-257000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	39000	USD
CY2016Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	300000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	500000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	100000	USD
CY2016Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-234000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-771000	USD
CY2017Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-89000	USD
	us-gaap	Interest Paid InterestPaid	508000	USD
	us-gaap	Interest Paid InterestPaid	92000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	12216000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	2504000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4700000	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	818000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8823000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11294000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1814000	USD
CY2016Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	2108000	USD
CY2017Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	101000	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	12080000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	11828000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2369000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	262000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11181000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8073000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-1291000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7134000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-3832000	USD
	us-gaap	Net Income Loss NetIncomeLoss	2800000	USD
	us-gaap	Net Income Loss NetIncomeLoss	2767000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	124000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3808000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-293000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1125000	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	6650000	USD
CY2017Q3	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	1720000	USD
	us-gaap	Operating Expenses OperatingExpenses	11152000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	3716000	USD
	us-gaap	Operating Expenses OperatingExpenses	8025000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1720000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11152000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3716000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8025000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	177000	USD
CY2017Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	118000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	60000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	35000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	76000	USD
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	54000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-23000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-26000	USD
CY2016Q3	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	400000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	641000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1235000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	177000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	216000	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	11500000	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	11500000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14785000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10733000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2200000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7800000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	164000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	100000	USD
CY2016Q3	us-gaap	Recapitalization Costs RecapitalizationCosts	256000	USD
	us-gaap	Recapitalization Costs RecapitalizationCosts	461000	USD
CY2017Q3	us-gaap	Recapitalization Costs RecapitalizationCosts	0	USD
	us-gaap	Recapitalization Costs RecapitalizationCosts	0	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	5000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2311000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7129000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	170000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5274000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1960000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3226000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-316308000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-313541000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1427000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	903000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0178
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0136
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	246914	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5199138	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	2317846	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7270070	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	24000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.23
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	415000	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	391000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.23
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.34
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	15.32
	us-gaap	Stock Issued1 StockIssued1	249000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-7516000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	6319000	USD
CY2016Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2017Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	800000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6632000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6108000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13208000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10781000	shares

Files In Submission

Name	View Source	Status
0001017491-17-000125-index-headers.html	Edgar Link	pending
0001017491-17-000125-index.html	Edgar Link	pending
0001017491-17-000125.txt	Edgar Link	pending
0001017491-17-000125-xbrl.zip	Edgar Link	pending
apri-20170930.xml	Edgar Link	completed
apri-20170930.xsd	Edgar Link	pending
apri-20170930_cal.xml	Edgar Link	unprocessable
apri-20170930_def.xml	Edgar Link	unprocessable
apri-20170930_lab.xml	Edgar Link	unprocessable
apri-20170930_pre.xml	Edgar Link	unprocessable
apri9301710q.htm	Edgar Link	pending
apri93017ex311.htm	Edgar Link	pending
apri93017ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SEEL
Seelos Therapeutics Inc Stock $seel

2017 Q4 Form 10-Q Financial Statement

#000101749117000125 Filed on November 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL Seelos Therapeutics Inc Stock $seel

2017 Q4 Form 10-Q Financial Statement

#000101749117000125 Filed on November 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL
Seelos Therapeutics Inc Stock $seel